SG11202000333UA - Bicyclic ketone compounds and methods of use thereof - Google Patents
Bicyclic ketone compounds and methods of use thereofInfo
- Publication number
- SG11202000333UA SG11202000333UA SG11202000333UA SG11202000333UA SG11202000333UA SG 11202000333U A SG11202000333U A SG 11202000333UA SG 11202000333U A SG11202000333U A SG 11202000333UA SG 11202000333U A SG11202000333U A SG 11202000333UA SG 11202000333U A SG11202000333U A SG 11202000333UA
- Authority
- SG
- Singapore
- Prior art keywords
- genentech
- san francisco
- south san
- international
- dna way
- Prior art date
Links
- -1 Bicyclic ketone compounds Chemical class 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102220240796 rs553605556 Human genes 0.000 abstract 2
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762532767P | 2017-07-14 | 2017-07-14 | |
| PCT/EP2018/068998 WO2019012063A1 (fr) | 2017-07-14 | 2018-07-12 | Composés cétoniques bicycliques et leurs procédés d'utilisation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202000333UA true SG11202000333UA (en) | 2020-02-27 |
Family
ID=62916677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202000333UA SG11202000333UA (en) | 2017-07-14 | 2018-07-12 | Bicyclic ketone compounds and methods of use thereof |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US11098058B2 (fr) |
| EP (2) | EP4397309A2 (fr) |
| JP (2) | JP7258843B2 (fr) |
| KR (2) | KR102664604B1 (fr) |
| CN (1) | CN110914271A (fr) |
| AR (1) | AR112274A1 (fr) |
| AU (3) | AU2018300043B2 (fr) |
| BR (1) | BR112020000771A2 (fr) |
| CA (2) | CA3067944C (fr) |
| CL (1) | CL2020000101A1 (fr) |
| CO (1) | CO2020000134A2 (fr) |
| CR (1) | CR20200002A (fr) |
| DK (1) | DK3652178T3 (fr) |
| ES (1) | ES2973661T3 (fr) |
| FI (1) | FI3652178T3 (fr) |
| HR (1) | HRP20240354T1 (fr) |
| IL (2) | IL294961A (fr) |
| LT (1) | LT3652178T (fr) |
| MA (1) | MA49560B1 (fr) |
| PH (1) | PH12020500105A1 (fr) |
| PL (1) | PL3652178T3 (fr) |
| PT (1) | PT3652178T (fr) |
| RS (1) | RS65308B1 (fr) |
| SG (1) | SG11202000333UA (fr) |
| SI (1) | SI3652178T1 (fr) |
| TW (1) | TWI805595B (fr) |
| UA (1) | UA125448C2 (fr) |
| WO (1) | WO2019012063A1 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3548484A1 (fr) | 2016-12-02 | 2019-10-09 | H. Hoffnabb-La Roche Ag | Composés amide bicycliques et leurs procédés d'utilisation |
| SG11202000333UA (en) | 2017-07-14 | 2020-02-27 | Hoffmann La Roche | Bicyclic ketone compounds and methods of use thereof |
| SG11202002877RA (en) | 2017-10-31 | 2020-04-29 | Hoffmann La Roche | Bicyclic sulfones and sulfoxides and methods of use thereof |
| WO2021198981A1 (fr) | 2020-04-01 | 2021-10-07 | Janssen Biopharma, Inc. | Composés antiviraux et leurs utilisations |
| TW202206407A (zh) * | 2020-04-27 | 2022-02-16 | 南韓商奧士擇破利悟股份有限公司 | 用於ｕｂｒ盒結構域配體之化合物、組成物以及醫藥組成物 |
| MX2023011482A (es) | 2021-04-02 | 2023-10-03 | Genentech Inc | Proceso para preparar compuestos de cetona biciclicos. |
| WO2023039795A1 (fr) * | 2021-09-16 | 2023-03-23 | 维泰瑞隆（北京）生物科技有限公司 | Inhibiteur de la kinase rip1 et son utilisation |
| US20240025912A1 (en) * | 2022-05-19 | 2024-01-25 | Merck Sharp & Dohme Llc | Ripk1 inhibitors and methods of use |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1620508A1 (de) | 1965-07-23 | 1969-09-18 | Thomae Gmbh Dr K | Verfahren zur Herstellung neuer 4,5,6,7-Tetrahydrothiazolo-[5,4-c]-pyridine |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US3948903A (en) | 1972-12-15 | 1976-04-06 | Parke, Davis & Company | Substituted N-(1,2-dihydro-2-oxonicotinyl)-cephalexins and -cephaloglycins |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| EP0102324A3 (fr) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipides et composés tensio-actifs en phase aqueuse |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| GB8610530D0 (en) | 1986-04-30 | 1986-06-04 | Fbc Ltd | Herbicides |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| EP0652775B1 (fr) | 1992-07-27 | 2000-04-19 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Ciblage de liposomes sur la barriere hemato-encephalique |
| US6080772A (en) | 1995-06-07 | 2000-06-27 | Sugen, Inc. | Thiazole compounds and methods of modulating signal transduction |
| EP1007042A4 (fr) | 1997-06-13 | 2001-07-04 | Sugen Inc | Nouveaux composes heteroaryle pour la modulation de la transduction de signaux cellulaires associee aux enzymes proteine tyrosine |
| CA2399791A1 (fr) * | 2000-02-11 | 2001-08-16 | Bristol-Myers Squibb Company | Modulateurs de recepteurs aux cannabinoides, leurs procedes de preparation et utilisations de modulateurs de recepteurs aux cannabinoides pour le traitement de maladies respiratoires et non respiratoires |
| US6514221B2 (en) | 2000-07-27 | 2003-02-04 | Brigham And Women's Hospital, Inc. | Blood-brain barrier opening |
| US20020065259A1 (en) | 2000-08-30 | 2002-05-30 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| US7034036B2 (en) | 2000-10-30 | 2006-04-25 | Pain Therapeutics, Inc. | Inhibitors of ABC drug transporters at the blood-brain barrier |
| DE10121982B4 (de) | 2001-05-05 | 2008-01-24 | Lts Lohmann Therapie-Systeme Ag | Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung |
| EP2147679B1 (fr) | 2001-07-25 | 2014-06-25 | Raptor Pharmaceutical, Inc. | Compositions pour le transport de barrière hématoencéphalique |
| US20030162695A1 (en) | 2002-02-27 | 2003-08-28 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| EP1572113B1 (fr) | 2002-08-26 | 2017-05-17 | Takeda Pharmaceutical Company Limited | Compose modulateur de recepteur de calcium et utilisation associee |
| KR101111477B1 (ko) | 2002-12-03 | 2012-02-23 | 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 | 치료제와 연결된 콜레스테롤을 포함하는 접합체 |
| WO2004098589A1 (fr) | 2003-05-02 | 2004-11-18 | Elan Pharmaceuticals, Inc. | Derives amides de l'acide carboxylique de 4- bromo - 5 - (2- chloro - benzoylamino) - 1h - pyrazole 3 et composes associes en tant qu'antagonistes de recepteur de b1 de la bradykinine pour le traitement de maladies inflammatoires |
| JP2007505142A (ja) | 2003-09-10 | 2007-03-08 | セダーズ−シナイ メディカル センター | 血液脳関門を通過する薬剤のカリウムチャネル媒介性送達 |
| JP2008539220A (ja) | 2005-04-26 | 2008-11-13 | ファイザー・リミテッド | バソプレシンアンタゴニストとしてのトリアゾール誘導体 |
| EP2083009A1 (fr) | 2008-01-22 | 2009-07-29 | Grünenthal GmbH | Composés tétrahydroimidazopyridine substitués et leur utilisation en tant que médicament |
| US8299077B2 (en) | 2009-03-02 | 2012-10-30 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
| CN101824036A (zh) | 2009-03-05 | 2010-09-08 | 上海恒瑞医药有限公司 | 四氢咪唑并[1，5-a]吡嗪衍生物的盐,其制备方法及其在医药上的应用 |
| TWI421252B (zh) | 2009-07-09 | 2014-01-01 | Irm Llc | 用於治療寄生蟲疾病之化合物及組合物 |
| CA2852964A1 (fr) | 2011-11-03 | 2013-05-10 | F. Hoffmann-La Roche Ag | Composes piperazines bicycliques |
| EP2852584B1 (fr) | 2012-05-22 | 2018-02-28 | F. Hoffmann-La Roche AG | Dipyridylamines substituées et leurs utilisations |
| CN104918934B (zh) | 2013-01-18 | 2017-12-22 | 霍夫曼-拉罗奇有限公司 | 3‑取代的吡唑及其作为dlk抑制剂的用途 |
| TWI648274B (zh) * | 2013-02-15 | 2019-01-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 （二） |
| EP2991977B1 (fr) | 2013-05-01 | 2020-07-22 | F.Hoffmann-La Roche Ag | Pyrimidines à substitution hétérocycloalkyle liées à c et leurs utilisations |
| MX2015015130A (es) | 2013-05-01 | 2016-02-18 | Hoffmann La Roche | Compuestos de biheteroarilo y usos de los mismos. |
| MX368728B (es) | 2013-07-10 | 2019-10-14 | Vertex Pharma | Amidas de piperidina fusionadas como moduladores de canales de iones. |
| MX2016008110A (es) | 2013-12-20 | 2016-08-19 | Hoffmann La Roche | Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos. |
| PE20161223A1 (es) | 2014-03-26 | 2016-11-12 | Hoffmann La Roche | Compuestos condensados de [1,4]diazepina como inhibidores de la produccion de autotaxina (atx) y acido lisofosfatidico (lpa) |
| WO2016027253A1 (fr) | 2014-08-21 | 2016-02-25 | Glaxosmithkline Intellectual Property Development Limited | Amides hétérocycliques utilisés comme inhibiteurs de la rip1 kinase en tant que médicaments |
| WO2016128908A1 (fr) * | 2015-02-12 | 2016-08-18 | Advinus Therapeutics Limited | Composés bicycliques, compositions et applications médicinales correspondantes |
| EP3268373B1 (fr) | 2015-03-09 | 2022-04-27 | F. Hoffmann-La Roche AG | Tricycliques inhibiteurs de dlk et leur utilisation |
| ES2930749T3 (es) | 2015-07-02 | 2022-12-21 | Hoffmann La Roche | Lactamas bicíclicas como inhibidores de la proteína de interacción con el receptor 1 (RIP1) cinasa para tratar, por ejemplo, enfermedades inflamatorias |
| WO2017096301A1 (fr) | 2015-12-04 | 2017-06-08 | Denali Therapeutics Inc. | Inhibiteurs dérivés d'isoxazolidine de protéine kinase 1 interagissant avec un récepteur (ripk 1) |
| WO2017109724A1 (fr) | 2015-12-21 | 2017-06-29 | Glaxosmithkline Intellectual Property Development Limited | Amides hétérocycliques utilisés en tant qu'inhibiteurs de kinase |
| MA44007A (fr) | 2016-02-05 | 2018-12-19 | Denali Therapeutics Inc | Inhibiteurs du récepteur interagissant avec protéine kinase 1 |
| EP3548484A1 (fr) | 2016-12-02 | 2019-10-09 | H. Hoffnabb-La Roche Ag | Composés amide bicycliques et leurs procédés d'utilisation |
| US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
| WO2018128908A1 (fr) | 2017-01-05 | 2018-07-12 | Microsoft Technology Licensing, Llc | Redirection de sortie audio |
| SG11202000333UA (en) | 2017-07-14 | 2020-02-27 | Hoffmann La Roche | Bicyclic ketone compounds and methods of use thereof |
| MA50356A (fr) | 2017-10-11 | 2021-04-21 | Hoffmann La Roche | Composés bicycliques destinés à être utilisés en tant qu'inhibiteurs de la kinase rip1 |
| SG11202002877RA (en) | 2017-10-31 | 2020-04-29 | Hoffmann La Roche | Bicyclic sulfones and sulfoxides and methods of use thereof |
-
2018
- 2018-07-12 SG SG11202000333UA patent/SG11202000333UA/en unknown
- 2018-07-12 AR ARP180101941 patent/AR112274A1/es unknown
- 2018-07-12 TW TW107124048A patent/TWI805595B/zh active
- 2018-07-12 WO PCT/EP2018/068998 patent/WO2019012063A1/fr active Application Filing
- 2018-07-12 KR KR1020207004030A patent/KR102664604B1/ko active IP Right Grant
- 2018-07-12 EP EP24152498.2A patent/EP4397309A2/fr active Pending
- 2018-07-12 AU AU2018300043A patent/AU2018300043B2/en active Active
- 2018-07-12 US US16/034,207 patent/US11098058B2/en active Active
- 2018-07-12 BR BR112020000771-4A patent/BR112020000771A2/pt unknown
- 2018-07-12 CN CN201880046714.2A patent/CN110914271A/zh active Pending
- 2018-07-12 CA CA3067944A patent/CA3067944C/fr active Active
- 2018-07-12 DK DK18740815.8T patent/DK3652178T3/da active
- 2018-07-12 RS RS20240314A patent/RS65308B1/sr unknown
- 2018-07-12 LT LTEPPCT/EP2018/068998T patent/LT3652178T/lt unknown
- 2018-07-12 IL IL294961A patent/IL294961A/en unknown
- 2018-07-12 UA UAA202000831A patent/UA125448C2/uk unknown
- 2018-07-12 SI SI201831080T patent/SI3652178T1/sl unknown
- 2018-07-12 FI FIEP18740815.8T patent/FI3652178T3/fi active
- 2018-07-12 IL IL271981A patent/IL271981B/en unknown
- 2018-07-12 PT PT187408158T patent/PT3652178T/pt unknown
- 2018-07-12 PL PL18740815.8T patent/PL3652178T3/pl unknown
- 2018-07-12 CR CR20200002A patent/CR20200002A/es unknown
- 2018-07-12 MA MA49560A patent/MA49560B1/fr unknown
- 2018-07-12 KR KR1020247014915A patent/KR20240065201A/ko active Search and Examination
- 2018-07-12 CA CA3185865A patent/CA3185865A1/fr active Pending
- 2018-07-12 HR HRP20240354TT patent/HRP20240354T1/hr unknown
- 2018-07-12 ES ES18740815T patent/ES2973661T3/es active Active
- 2018-07-12 JP JP2020501256A patent/JP7258843B2/ja active Active
- 2018-07-12 EP EP18740815.8A patent/EP3652178B1/fr active Active
-
2020
- 2020-01-08 CO CONC2020/0000134A patent/CO2020000134A2/es unknown
- 2020-01-13 CL CL2020000101A patent/CL2020000101A1/es unknown
- 2020-01-14 PH PH12020500105A patent/PH12020500105A1/en unknown
-
2021
- 2021-01-12 US US17/147,449 patent/US11834461B2/en active Active
- 2021-06-26 AU AU2021204369A patent/AU2021204369A1/en not_active Abandoned
-
2023
- 2023-04-05 JP JP2023061174A patent/JP2023085449A/ja active Pending
- 2023-05-25 AU AU2023203292A patent/AU2023203292A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201804373VA (en) | Compositions and methods for immunooncology | |
| SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
| SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201900443VA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
| SG11201809830WA (en) | Selective reduction of cysteine-engineered antibodies | |
| SG11201900021PA (en) | Methods and compositions for the treatment of cancer |